CCDC92

Across TCGA pan-cancer cohorts, CCDC92 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC92 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCDC92 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CCDC92 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where CCDC92 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.939	.012	14	view →
LUAD	DFS	Median	All	1.000	0.639	.001	13	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	7	view →
LSCC	DFS	Tertile	III,IV	0.439	0.916	.011	6	view →
PDAC	OS	Median	IV	0.643	0.836	.038	3	view →
GBM	DFS	Tertile	All	0.855	0.639	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC92–HNSC (OS)

Open the HNSC breakdown →